$CYCC While Cyclacel CEO Spiro Rombotis has you focused on our cutting edge, 2nd generation CDK-Inhibitor (CYC065) my eyes remain fixed on an outpatient study with filing implications in Europe clinicaltrials.gov/ct2/show... This all oral combo therapy of Abbvie’s Venclexta and Cyclacel’s Sapacitabine will offer highly compromised elderly AML & MDS patients the opportunity to get better at home without traveling to a medical facility for an I.V. administration of Docogen. Not only is this approach compassionate but it saves the healthcare system money as no one is needed to insert the needle, mount the hose or regulate the intravenous therapy . Only a capsule need be swallowed. In addition to MD Anderson’s Texas facility, 2 outpatient care networks have been activated in New York and Chicago. Here’s one of them...
  • 1
  • 6